Empowering Patient Safety: Assessment of Adverse Drug Reaction Knowledge and Practice Among Pharmacy Professionals
Abstract
:1. Introduction
2. Materials and Methods
3. Results
3.1. Attitudes on Reporting Adverse Drug Reactions
3.2. Reporting Adverse Drug Reactions
3.3. ADR-Adverse Drug Reaction
4. Discussion
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Sabaté, M.; Montané, E. Pharmacoepidemiology: An Overview. J. Clin. Med. 2023, 12, 7033. [Google Scholar] [CrossRef]
- World Health Organization. What Is Pharmacovigilance? Available online: https://www.who.int/teams/regulation-prequalification/regulation-and-safety/pharmacovigilance (accessed on 2 October 2024).
- European Medicines Agency. Good pharmacovigilance practices (GVP). Available online: https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/pharmacovigilance-post-authorisation/good-pharmacovigilance-practices-gvp (accessed on 2 October 2024).
- Khan, M.A.A.; Hamid, S.; Babar, Z.-U.-D. Pharmacovigilance in High-Income Countries: Current Developments and a Review of Literature. Pharmacy 2023, 11, 10. [Google Scholar] [CrossRef]
- Leskur, D.; Bozic, J.; Rusic, D.; Seselja Perisin, A.; Cohadzic, T.; Pranic, S.; Modun, D.; Bukic, J. Adverse drug reaction reporting via mobile applications: A narrative review. Int. J. Med. Inform. 2022, 168, 104895. [Google Scholar] [CrossRef] [PubMed]
- Agustí, A.; Cereza, G.; de Abajo, F.J.; Maciá, M.A.; Sacristán, J.A. Clinical pharmacology facing the real-world setting: Pharmacovigilance, pharmacoepidemiology and the economic evaluation of drugs. Pharmacol. Res. 2023, 197, 106967. [Google Scholar] [CrossRef] [PubMed]
- Khan, M.A.A.; Sara, T.; Babar, Z.U. Pharmacovigilance: The evolution of drug safety monitoring. J. Pharm. Policy Pract. 2024, 17, 2417399. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Dores, A.R.; Peixoto, M.; Carvalho, I.P.; Jesus, Â.; Moreira, F.; Marques, A. The Pharmacy of the Future: Pharmacy Professionals’ Perceptions and Contributions Regarding New Services in Community Pharmacies. Healthcare 2023, 11, 2580. [Google Scholar] [CrossRef] [PubMed]
- Karłowicz-Bodalska, K.; Sauer, N.; Jonderko, L.; Wiela-Hojeńska, A. Over the Counter Pain Medications Used by Adults: A Need for Pharmacist Intervention. Int. J. Environ. Res. Public Health 2023, 20, 4505. [Google Scholar] [CrossRef]
- Hamadouk, R.M.; Mohammed, F.M.; Albashair, E.D.; Yousef, B.A. Evaluation of Community Pharmacists’ Competences in Identifying and Resolve Drug-Related Problems in a Pediatric Prescription Using the Simulated Patient Method. Pharmacy 2023, 11, 6. [Google Scholar] [CrossRef] [PubMed]
- Li, R.; Curtain, C.; Bereznicki, L.; Zaidi, S.T.R. Community pharmacists’ knowledge and perspectives of reporting adverse drug reactions in Australia: A cross-sectional survey. Int. J. Clin. Pharm. 2018, 40, 878–889. [Google Scholar] [CrossRef]
- Bukic, J.; Kuzmanic, B.; Rusic, D.; Portolan, M.; Mihanovic, A.; Seselja Perisin, A.; Leskur, D.; Petric, A.; Bozic, J.; Tomic, S.; et al. Community pharmacists’ use, perception and knowledge on dietary supplements: A cross sectional study. Pharm. Pract. 2021, 19, 2251. [Google Scholar] [CrossRef]
- Al-Worafi, Y.M.; Kassab, Y.W.; Alseragi, W.M.; Almutairi, M.S.; Ahmed, A.; Ming, L.C.; Alkhoshaiban, A.S.; Hadi, M.A. Pharmacovigilance and adverse drug reaction reporting: A perspective of community pharmacists and pharmacy technicians in Sana’a, Yemen. Ther. Clin. Risk Manag. 2017, 13, 1175–1181. [Google Scholar] [CrossRef] [PubMed]
- Laven, A.; Schmitz, K.; Franzen, W.H. Reporting adverse drug reactions: Contribution, knowledge and perception of German pharmacy professionals. Int. J. Clin. Pharm. 2018, 40, 842–851. [Google Scholar] [CrossRef] [PubMed]
- Al-Omrani, H.; Marwah, M.K.; Al-Whaib, R.; Mekkawy, M.; Shokr, H. Patterns of Drug Utilization and Self-Medication Practices: A Cross Sectional Study. Pharmacy 2023, 11, 183. [Google Scholar] [CrossRef] [PubMed]
- Valliant, S.N.; Burbage, S.C.; Pathak, S.; Urick, B.Y. Pharmacists as accessible health care providers: Quantifying the opportunity. J. Manag. Care Spec. Pharm. 2022, 28, 85–90. [Google Scholar] [CrossRef] [PubMed]
- Isenor, J.E.; Renaud, L.; Mathews, M.; Morrison, B.; Murphy, A.L.; Bishop, A.; Bowles, S.K.; Kennie-Kaulbach, N.; Peddle, S.; Breton, M.; et al. Patient perspectives on the vital primary care role of community pharmacists in Nova Scotia, Canada: Qualitative findings from the PUPPY Study. Int. J. Pharm. Pract. 2024, 32, 216–222. [Google Scholar] [CrossRef]
- Abdulsalim, S.; Farooqui, M.; Alshammari, M.S.; Alotaibi, M.; Alhazmi, A.; Alqasomi, A.; Altowayan, W.M. Evaluation of Knowledge, Attitudes, and Practices about Pharmacovigilance among Community Pharmacists in Qassim, Saudi Arabia. Int. J. Environ. Res. Public Health 2023, 20, 3548. [Google Scholar] [CrossRef] [PubMed]
- Li, R.; Curtis, K.; Zaidi, S.T.; Van, C.; Castelino, R. A new paradigm in adverse drug reaction reporting: Consolidating the evidence for an intervention to improve reporting. Expert Opin. Drug Saf. 2022, 21, 1193–1204. [Google Scholar] [CrossRef] [PubMed]
- Choo, S.; Sartori, D.; Lee, S.; Yang, H.; Syed-Abdul, S. Data-Driven Identification of Factors That Influence the Quality of Adverse drug reaction Reports: 15-Year Interpretable Machine Learning and Time-Series Analyses of VigiBase and QUEST. JMIR Med. Inform. 2024, 12, e49643. [Google Scholar] [CrossRef]
- Uppasal Monitoring Centre. Medsafetyweek. 2024. Available online: https://who-umc.org/medsafetyweek/ (accessed on 3 October 2024).
- Rudolph, A.; Mitchell, J.; Barrett, J.; Sköld, H.; Taavola, H.; Erlanson, N.; Melgarejo-González, C.; Yue, Q.Y. Global safety monitoring of COVID-19 vaccines: How pharmacovigilance rose to the challenge. Ther. Adv. Drug Saf. 2022, 13, 20420986221118972. [Google Scholar] [CrossRef]
- Halmed. Izvješće o Nuspojavama u 2023. Godini, 2023. Available online: https://www.halmed.hr/en/Novosti-i-edukacije/Publikacije-i-izvjesca/Izvjesca-o-nuspojavama/ (accessed on 3 October 2024).
- Mucalo, I.; Hadžiabdić, M.O.; Govorčinović, T.; Šarić, M.; Bruno, A.; Bates, I. The Development of the Croatian Competency Framework for Pharmacists. American journal of pharmaceutical education. Am. J. Pharm. Educ. 2016, 80, 134. [Google Scholar] [CrossRef]
- Spanakis, M.; Sfakianakis, S.; Kallergis, G.; Spanakis, E.G.; Sakkalis, V. PharmActa: Personalized pharmaceutical care eHealth platform for patients and pharmacists. J. Biomed. Inform. 2019, 100, 103336. [Google Scholar] [CrossRef] [PubMed]
- Hayek, A.; Sridhar, S.B.; Rabbani, S.A.; Shareef, J.; Wadhwa, T. Exploring pharmacovigilance practices and knowledge among healthcare professionals: A cross-sectional multicenter study. SAGE Open Med. 2024, 12, 20503121241249908. [Google Scholar] [CrossRef]
- Shalviri, G.; Mohebbi, N.; Mirbaha, F.; Majdzadeh, R.; Yazdizadeh, B.; Gholami, K.; Grobler, L.; Rose, C.J.; Chin, W.Y. Improving adverse drug event reporting by healthcare professionals. Cochrane Database Syst. Rev. 2024, 10, CD012594. [Google Scholar] [CrossRef] [PubMed]
N | Proportion | ||
---|---|---|---|
Sex | Female | 154 | 85.56% |
Male | 26 | 14.44% | |
Age | 18–30 | 67 | 37.22% |
31–40 | 64 | 35.56% | |
41–50 | 37 | 20.56% | |
51–60 | 9 | 5.00% | |
61–70 | 3 | 1.67% | |
Work experience in years | <5 | 65 | 36.11% |
5–10 | 39 | 21.67% | |
10–15 | 22 | 12.22% | |
15–20 | 24 | 13.33% | |
>20 | 30 | 16.67% | |
Profession | Pharmacy technician | 37 | 20.56% |
Pharmacist | 143 | 79.44% | |
Chronic use of drugs | No | 133 | 73.89% |
Yes | 47 | 26.11% | |
Number of reported adverse drug reactions | 0 | 49 | 27.22% |
<5 | 69 | 38.33% | |
5–15 | 45 | 25.00% | |
16–30 | 10 | 5.56% | |
>30 | 7 | 3.89% |
Count | N% | ||
---|---|---|---|
Pharmacovigilance definiton | Incorrect | 25 | 13.89% |
Correct | 155 | 86.11% | |
Adverse drug reaction example | Incorrect | 123 | 68.33% |
Correct | 57 | 31.67% | |
Type of reaction national authority requires healthcare professionals to report | Incorrect | 7 | 3.89% |
Correct | 173 | 96.11% | |
Acceptable reporters of adverse drug reactions | Incorrect | 11 | 6.11% |
Correct | 169 | 93.89% | |
Phase where the most data on drug safety are collected | Incorrect | 65 | 36.11% |
Correct | 115 | 63.89% | |
Most common safety reason for withdrawal of a drug from the market | Incorrect | 116 | 64.44% |
Correct | 64 | 35.56% |
Mean Rank | p-Value | ||
---|---|---|---|
Sex | Female | 91.41 | 0.553 |
Male | 85.12 | ||
Age | 18–30 | 91.03 | 0.647 |
31–40 | 96.61 | ||
41–50 | 82.19 | ||
51–60 | 79.00 | ||
61–70 | 85.33 | ||
Work experience in years | <5 | 107.16 | 0.001 * |
5–10 | 68.15 | ||
10–15 | 104.20 | ||
15–20 | 88.63 | ||
>20 | 74.90 | ||
Profession | Pharmacy technician | 73.97 | 0.024 * |
Pharmacist | 94.78 | ||
Chronic use of medication | No | 85.39 | 0.021 * |
Yes | 104.96 | ||
Number of reported adverse drug reactions | 0 | 81.07 | 0.047 * |
<5 | 92.97 | ||
5–15 | 93.46 | ||
16–30 | 126.70 | ||
>30 | 61.43 |
Strongly Disagree | Disagree | Nor Agree or Disagree | Agree | Strongly Agree | |
---|---|---|---|---|---|
Count (%) | Count (%) | Count (%) | Count (%) | Count (%) | |
Reporting adverse effects is a part of pharmaceutical care. | 0 (0.00) | 1 (0.56) | 4 (2.22) | 75 (41.67) | 100 (55.56) |
Reporting adverse effects should be mandatory for all pharmacy professionals. | 3 (1.67) | 3 (1.67) | 15 (8.33) | 81 (45.00) | 78 (43.33) |
I do not have time to report adverse effects during my work hours. | 30 (16.67) | 45 (25.00) | 53 (29.44) | 38 (21.11) | 14 (7.78) |
Patients do not share information about adverse effects with us. | 15 (8.33) | 57 (31.67) | 66 (36.67) | 35 (19.44) | 7 (3.89) |
I believe that the vaccines for the SARS-CoV-2 pandemic have increased awareness about the importance of reporting adverse effects. | 4 (2.22) | 26 (14.44) | 68 (37.78) | 69 (38.33) | 13 (7.22) |
I currently have sufficient knowledge and training on how to report adverse effects. | 1 (0.56) | 20 (11.11) | 28 (15.56) | 91 (50.56) | 40 (22.22) |
I am concerned that reporting adverse effects to the national authority may lead to legal consequences. | 63 (35.00) | 84 (46.67) | 24 (13.33) | 8 (4.44) | 1 (0.56) |
I believe it is not necessary to report adverse effects to herbal medicines. | 88 (48.89) | 81 (45.00) | 8 (4.44) | 2 (1.11) | 1 (0.56) |
I would be motivated to report adverse effects if I were rewarded for doing so. | 20 (11.11) | 29 (16.11) | 57 (31.67) | 44 (24.44) | 30 (16.67) |
I believe there is no need to report well-known adverse effects. | 55 (30.56) | 68 (37.78) | 31 (17.22) | 22 (12,22) | 4 (2.22) |
Proportion of Participants That Had Report ADR | p-Value | ||
---|---|---|---|
Age | 18–30 | 64.2 | 0.160 |
31–40 | 71.9 | ||
41–50 | 83.8 | ||
51–60 | 88.9 | ||
61–70 | 100.0 | ||
Work experience in years | <5 | 64.6 | 0.326 |
5–10 | 74.4 | ||
10–15 | 81.8 | ||
15–20 | 70.8 | ||
>20 | 83.3 | ||
Profession | Pharmacy technician | 43.2 | <0.001 * |
Pharmacist | 80.4 | ||
Chronic use of medication | No | 67.7 | 0.012 * |
Yes | 87.2 |
Variable | B | Exp (B) | 95%CI for B | p-Value | |
---|---|---|---|---|---|
Lower Bound | Upper Bound | ||||
Chronic use of medication | |||||
Yes | Ref. | ||||
No | −1.369 | 0.254 | 0.094 | −0.256 | 0.007 * |
Profession | |||||
Pharmacist | ref. | ||||
Pharmacy technician | −1.810 | 0.164 | −2.430 | 0.073 | <0.001 * |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Bukić, J.; Leskur, D.; Durdov, T.; Božić, J.; Modun, D.; Šešelja Perišin, A.; Ančić, D.; Šepetavc, M.; Mihanović, A.; Rušić, D. Empowering Patient Safety: Assessment of Adverse Drug Reaction Knowledge and Practice Among Pharmacy Professionals. Pharmacy 2025, 13, 1. https://doi.org/10.3390/pharmacy13010001
Bukić J, Leskur D, Durdov T, Božić J, Modun D, Šešelja Perišin A, Ančić D, Šepetavc M, Mihanović A, Rušić D. Empowering Patient Safety: Assessment of Adverse Drug Reaction Knowledge and Practice Among Pharmacy Professionals. Pharmacy. 2025; 13(1):1. https://doi.org/10.3390/pharmacy13010001
Chicago/Turabian StyleBukić, Josipa, Dario Leskur, Toni Durdov, Joško Božić, Darko Modun, Ana Šešelja Perišin, Daniela Ančić, Martina Šepetavc, Ante Mihanović, and Doris Rušić. 2025. "Empowering Patient Safety: Assessment of Adverse Drug Reaction Knowledge and Practice Among Pharmacy Professionals" Pharmacy 13, no. 1: 1. https://doi.org/10.3390/pharmacy13010001
APA StyleBukić, J., Leskur, D., Durdov, T., Božić, J., Modun, D., Šešelja Perišin, A., Ančić, D., Šepetavc, M., Mihanović, A., & Rušić, D. (2025). Empowering Patient Safety: Assessment of Adverse Drug Reaction Knowledge and Practice Among Pharmacy Professionals. Pharmacy, 13(1), 1. https://doi.org/10.3390/pharmacy13010001